Ilmarinen Mutual Pension Insurance Co Grows Stake in Pfizer Inc. (NYSE:PFE)

Ilmarinen Mutual Pension Insurance Co lifted its stake in Pfizer Inc. (NYSE:PFE) by 48.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 982,000 shares of the biopharmaceutical company’s stock after buying an additional 322,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Pfizer were worth $26,052,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PFE. Russell Investments Group Ltd. increased its position in shares of Pfizer by 2.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,798,470 shares of the biopharmaceutical company’s stock valued at $100,752,000 after acquiring an additional 73,526 shares in the last quarter. Rahlfs Capital LLC purchased a new stake in Pfizer during the 4th quarter valued at $1,060,000. Hurley Capital LLC bought a new stake in shares of Pfizer in the 4th quarter worth $86,000. Ted Buchan & Co purchased a new position in shares of Pfizer in the fourth quarter worth $700,000. Finally, Wedbush Securities Inc. lifted its holdings in shares of Pfizer by 2.9% during the fourth quarter. Wedbush Securities Inc. now owns 202,238 shares of the biopharmaceutical company’s stock valued at $5,365,000 after purchasing an additional 5,697 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $22.99 on Friday. The business has a 50-day simple moving average of $25.87 and a two-hundred day simple moving average of $26.76. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $22.95 and a 52 week high of $31.54. The stock has a market cap of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.10 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.